Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of LupusErythematosus

Abstract

Based on the results of this case series, we believe that thalidomide should be given prime consideration as a treatment for antimalarial drug-resistant interface lesions of LE. The design of prospective, randomized, double-blind, placebo-controlled trials for this indication is warranted.